Trastuzumab biosimilar - Shanghai Henlius Biotech

Drug Profile

Trastuzumab biosimilar - Shanghai Henlius Biotech

Alternative Names: HLX 02

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Henlius Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • No development reported Gastric cancer

Most Recent Events

  • 01 Nov 2016 Phase-III clinical trials in Breast cancer (Early-stage disease, Locally recurrent, Metastatic disease) in China (IV) (NCT03084237)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gastric-cancer in China (IV)
  • 01 Sep 2015 Phase-I clinical trials in Breast cancer (In volunteers) in China (IV) (NCT02581748)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top